On December 1, 2025, Belite Bio, a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced the pricing of an underwritten public offering at approximately $350 million. Wilson Sonsini Goodrich & Rosati has advised Belite Bio on patent matters since the company's inception, in addition to FDA regulatory, licensing, and litigation matters, and counseled Belite on patent matters related to this latest offering.

The company priced the underwritten public offering of 2,272,727 American Depositary Shares (ADSs), each representing one of its ordinary shares, at a public offering price of $154 per ADS. Belite Bio has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the company at the public offering price, less underwriting discounts and commissions. Belite Bio intends to use the proceeds of the offering for commercialization preparation, including building an in-house commercialization team, establishing a sales network and systems, and preparing for the commercial manufacture of future products, as well as developing and expanding pipelines and other general corporate purposes.

The team that advised Belite Bio on the transaction was led by Matthew Bresnahan and August Renshaw.

For more information, please see Belite Bio’s press release.